NCT05335473 2023-04-06Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor FailureHenan Cancer HospitalPhase 1/2 Unknown87 enrolled